U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H20N4O3S
Molecular Weight 348.4217
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TORSEMIDE

SMILES

CC(C)N=C(NS(=O)(=O)c1c[nH]ccc1=Nc2cccc(C)c2)O

InChI

InChIKey=NGBFQHCMQULJNZ-UHFFFAOYSA-N
InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020136s023lbl.pdf

Torasemide is a pyridine-sulfonylurea type loop diuretic mainly used for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Also for the treatment of hypertension alone or in combination with other antihypertensive agents. It is also used at low doses for the management of hypertension. It is marketed under the brand name Demadex. Torasemide inhibits the Na+/K+/2Cl--carrier system (via interference of the chloride binding site) in the lumen of the thick ascending portion of the loop of Henle, resulting in a decrease in reabsorption of sodium and chloride. This results in an increase in the rate of delivery of tubular fluid and electrolytes to the distal sites of hydrogen and potassium ion secretion, while plasma volume contraction increases aldosterone production. The increased delivery and high aldosterone levels promote sodium reabsorption at the distal tubules, and by increasing the delivery of sodium to the distal renal tubule, torasemide indirectly increases potassium excretion via the sodium-potassium exchange mechanism. Torasemide's effects in other segments of the nephron have not been demonstrated. Thus torasemide increases the urinary excretion of sodium, chloride, and water, but it does not significantly alter glomerular filtration rate, renal plasma flow, or acid-base balance. Torasemide's effects as a antihypertensive are due to its diuretic actions. By reducing extracellular and plasma fluid volume, blood pressure is reduced temporarily, and cardiac output also decreases.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Demadex

Approved Use

Demadex is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. Demadex is indicated for the treatment of hypertension alone or in combination with other antihypertensive agents.

Launch Date

7.4597761E11
Primary
Demadex

Approved Use

Demadex is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. Demadex is indicated for the treatment of hypertension alone or in combination with other antihypertensive agents.

Launch Date

7.4597761E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
968.7 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TORSEMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1549.9 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TORSEMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1561 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TORSEMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
3516 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TORSEMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.4 h
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TORSEMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.5 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TORSEMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TORSEMIDE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.124
unhealthy
Health Status: unhealthy
Condition: Chronic renal failure
Sources: Page: p.124
800 mg single, intravenous
Highest studied dose
Dose: 800 mg
Route: intravenous
Route: single
Dose: 800 mg
Sources: Page: p.124, 133
unhealthy
Health Status: unhealthy
Condition: Acute renal failure
Sources: Page: p.124, 133
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease
Sources: Page: p.11
Disc. AE: Dizziness, Headache...
AEs leading to
discontinuation/dose reduction:
Dizziness (0.1 - 0.5)
Headache (0.1 - 0.5)
Nausea (0.1 - 0.5)
Weakness (0.1 - 0.5)
Vomiting (0.1 - 0.5)
Hyperglycemia (0.1 - 0.5)
Urination abnormal NOS (0.1 - 0.5)
Hyperuricemia (0.1 - 0.5)
Hypokalemia (0.1 - 0.5)
Excessive thirst (0.1 - 0.5)
Hypovolemia (0.1 - 0.5)
Impotence (0.1 - 0.5)
Esophageal hemorrhage (0.1 - 0.5)
Dyspepsia (0.1 - 0.5)
Sources: Page: p.11
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease
Sources: Page: p.6
Disc. AE: Electrolyte depletion, Electrolyte depletion...
Other AEs: Hepatic coma, Tinnitus...
AEs leading to
discontinuation/dose reduction:
Electrolyte depletion
Electrolyte depletion
Hypokalemia
Other AEs:
Hepatic coma
Tinnitus
Hearing loss
Sources: Page: p.6
200 mg 1 times / day multiple, intravenous
Studied dose
Dose: 200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
n = 44
Health Status: unhealthy
Condition: Advanced chronic renal failure
Population Size: 44
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease
Sources: Page: p.11
Dyspepsia 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease
Sources: Page: p.11
Esophageal hemorrhage 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease
Sources: Page: p.11
Excessive thirst 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease
Sources: Page: p.11
Headache 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease
Sources: Page: p.11
Hyperglycemia 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease
Sources: Page: p.11
Hyperuricemia 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease
Sources: Page: p.11
Hypokalemia 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease
Sources: Page: p.11
Hypovolemia 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease
Sources: Page: p.11
Impotence 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease
Sources: Page: p.11
Nausea 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease
Sources: Page: p.11
Urination abnormal NOS 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease
Sources: Page: p.11
Vomiting 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease
Sources: Page: p.11
Weakness 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease
Sources: Page: p.11
Hearing loss
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease
Sources: Page: p.6
Hepatic coma
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease
Sources: Page: p.6
Tinnitus
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease
Sources: Page: p.6
Electrolyte depletion Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease
Sources: Page: p.6
Electrolyte depletion Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease
Sources: Page: p.6
Hypokalemia Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Edema associated with congestive heart failure, renal disease, or hepatic disease
Sources: Page: p.6
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer






Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [Inhibition 100 uM]
yes [Inhibition 100 uM]
yes [Inhibition 100 uM]
Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Torasemide. A review of its pharmacological properties and therapeutic potential.
1991 Jan
[Treatment of ascites in cirrhotic patients].
2001 Sep
Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous torasemide in rats.
2003
[Torasemide (Trifas) in clinical practice--own experience].
2003
[Diuretics in heart failure. Fewer electrolyte disorders -- better prognosis].
2003 Aug 7
Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV--efficacy and quality of life.
2003 Dec
[Favorable prognostic effect of heart failure therapy. Diuretic makes heart muscle more elastic].
2003 Jun 5
The effects of the loop diuretics furosemide and torasemide on diuresis in dogs and cats.
2003 Oct
Calciphylaxis in chronic, non-dialysis-dependent renal disease.
2003 Sep 29
Pharmacotherapy in congestive heart failure: drug absorption in the management of congestive heart failure: loop diuretics.
2003 Sep-Oct
CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.
2004 Dec
Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs).
2004 Feb 23
Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of torasemide in rabbits.
2004 Jul
Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure.
2004 Jun 2
[Idiopathic hypereosinophilia with cardiac involvement].
2004 Mar 12
Food: an unrecognized source of loop diuretic resistance.
2004 May
Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time.
2004 May
Pharmacological evaluation of both enantiomers of (R,S)-BM-591 as thromboxane A2 receptor antagonists and thromboxane synthase inhibitors.
2004 Oct
[Valsartan in patients with arterial hypertension and type 2 diabetes mellitus. The lapaval study].
2005
[The place of diuretics in the treatment of chronic heart failure. Part I].
2005
Torsemide versus furosemide after continuous renal replacement therapy due to acute renal failure in cardiac surgery patients.
2005
Screening procedure for detection of diuretics and uricosurics and/or their metabolites in human urine using gas chromatography-mass spectrometry after extractive methylation.
2005 Aug
Functional characterization of human monocarboxylate transporter 6 (SLC16A5).
2005 Dec
[Aldosterone antagonist therapy for chronic heart failure].
2005 Feb 10
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Electrochemical characterisation of the human cytochrome P450 CYP2C9.
2005 May 15
Comparison of the urine acidification tests of torsemide vs furosemide in healthy volunteers.
2005 Nov
Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin.
2005 Nov
[Torasemide--new generation loop diuretic: clinical pharmacology and therapeutic application].
2006
[A case of severe hyponatremia in a patient suffering from epilepsy and using oxcarbazepine].
2006
[Clinical efficacy and safety of administration of loop diuretic torasemide].
2006
Probable loop diuretic-induced pancreatitis in a sulfonamide-allergic patient.
2006 Jan
[Diuretic therapy in heart failure].
2006 Jan-Feb
Cardiomyopathy, familial dilated.
2006 Jul 13
Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report.
2006 Jul 17
Relation of loop diuretic dose to mortality in advanced heart failure.
2006 Jun 15
Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs.
2006 Nov
Dose-dependent association between use of loop diuretics and mortality in advanced systolic heart failure.
2006 Nov 15
Efficacy and safety of a furosemide continuous infusion following cardiac surgery.
2006 Oct
Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure.
2006 Oct
Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters.
2006 Sep
Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents.
2006 Sep
Hospital policies for treatment of acute decompensated heart failure.
2007 Apr
Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats.
2007 Apr
Genetic variation at the CYP2C locus and its association with torsemide biotransformation.
2007 Jun
Effect of torsemide on serum and urine electrolyte levels in dogs with congestive heart failure.
2007 Jun 16
Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis.
2007 Mar
Secondary pulmonary hypertension: haemodynamic effects of torasemide versus furosemide.
2008
Comparative effects of torasemide and furosemide in rats with heart failure.
2008 Feb 1
Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy.
2008 Feb 26
Patents

Sample Use Guides

Congestive Heart Failure The usual initial dose is 10 mg or 20 mg of once-daily oral Demadex (Torasemide). If the diuretic response is inadequate, the dose should be titrated upward by approximately doubling until the desired diuretic response is obtained. Single doses higher than 200 mg have not been adequately studied. Chronic Renal Failure The usual initial dose of Demadex is 20 mg of once-daily oral Demadex. Hypertension The usual initial dose is 5 mg once daily. If the 5 mg dose does not provide adequate reduction in blood pressure within 4 to 6 weeks, the dose may be increased to 10 mg once daily.
Route of Administration: Oral
Isometric contraction induced by a submaximal concentration of Ang II (10(-7) mol/L) was reduced in a dose-dependent way by torasemide (IC(50)=0.5+/-0.04 umol/L) in cultured vascular smooth muscle cells (VSMCs) from spontaneously hypertensive rats..
Name Type Language
TORSEMIDE
MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF  
USAN  
Official Name English
LUPRAC
Brand Name English
TORSEMIDE [MI]
Common Name English
TORSEMIDE [USAN]
Common Name English
TORSEMIDE [VANDF]
Common Name English
TORSEMIDE [USP MONOGRAPH]
Common Name English
TORASEMIDE [JAN]
Common Name English
1-ISOPROPYL-3-((4-M-TOLUIDINO-3-PYRIDYL)SULPHONYL)UREA
Systematic Name English
TORSEMIDE [ORANGE BOOK]
Common Name English
TORASEMIDE [EP MONOGRAPH]
Common Name English
TORASEMIDE [INN]
Common Name English
TORASEMIDE
INN   JAN   MART.   WHO-DD  
INN  
Official Name English
TORSEMIDE [USP-RS]
Common Name English
3-PYRIDINESULFONAMIDE, N-(((1-METHYLETHYL)AMINO)CARBONYL)-4-((3-METHYLPHENYL)AMINO)-
Systematic Name English
AC4464
Code English
AC-4464
Code English
TORASEMIDE [MART.]
Common Name English
BM02.015
Code English
BM-02015
Code English
TORASEMIDE [WHO-DD]
Common Name English
UPCARD
Brand Name English
TORASEMIDE ANHYDROUS [EMA EPAR VETERINARY]
Common Name English
BM-02.015
Code English
TORSEMIDE [USP]
Common Name English
TORASEMIDE ANHYDROUS
Common Name English
Classification Tree Code System Code
WHO-VATC QC03CA04
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
LIVERTOX 984
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
WHO-ATC C03CA04
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
NDF-RT N0000175366
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
NCI_THESAURUS C49184
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
EMA VETERINARY ASSESSMENT REPORTS UPCARD [AUTHORIZED]
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
NDF-RT N0000175590
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
Code System Code Type Description
WIKIPEDIA
TORASEMIDE
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
PRIMARY
NCI_THESAURUS
C29506
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
PRIMARY
DRUG BANK
DB00214
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
PRIMARY
CAS
56211-40-6
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
PRIMARY
DRUG CENTRAL
2708
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
PRIMARY
ChEMBL
CHEMBL1148
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
PRIMARY
EVMPD
SUB11195MIG
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
PRIMARY
MESH
C026116
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
PRIMARY
IUPHAR
7312
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
PRIMARY
USP_CATALOG
1672304
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
PRIMARY USP-RS
RXCUI
38413
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
PRIMARY RxNorm
INN
3938
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
PRIMARY
EPA CompTox
56211-40-6
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
PRIMARY
PUBCHEM
41781
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
PRIMARY
MERCK INDEX
M10981
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
PRIMARY Merck Index
LACTMED
Torsemide
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
PRIMARY
FDA UNII
W31X2H97FB
Created by admin on Fri Jun 25 20:55:59 UTC 2021 , Edited by admin on Fri Jun 25 20:55:59 UTC 2021
PRIMARY